ALKS:NASDAQ
Alkermes Plc
$40.61
arrow_upward
+1.25%(+0.50) 1D
$40.65
arrow_upward
+0.10% (+0.040)bedtimeAfter hours
Closed: Oct 9, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALKS...
Open
$40.18
High
$40.87
Low
$39.99
Mkt. cap
6.81B
Avg. vol.
2.20M
Volume
1.63M
P/E ratio
105.52
52-wk high
$55.67
52-wk low
$27.00
EPS
$0.38
Beta
0.29
Shares outstanding
167.76M
No. of employees
2K
Open
$40.18
High
$40.87
Low
$39.99
Mkt. cap
6.81B
Avg. vol.
2.20M
Volume
1.63M
P/E ratio
105.52
52-wk high
$55.67
52-wk low
$27.00
EPS
$0.38
Beta
0.29
Shares outstanding
167.76M
No. of employees
2K
News stories
From web sources and news partners
Investing.com Nigeria
·
1 hour ago
Form 4 Alkermes plc. For: 11 October By Investing.com
The Globe and Mail
·
1 day ago
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Alkermes (ALKS)
Profile
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. Wikipedia
About Alkermes Plc
CEORichard F. Pops | Richard F. Pops
Employees2.05K
Founded1987
Headquarters-
SectorBiotechnology
Websitealkermes.com